Vai trò của biểu hiện mRNA thymidylate synthase và dihydropyrimidine dehydrogenase trong ung thư túi mật

De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368–78. Cereda S, Passoni P, Reni M, Viganò MG, Aldrighetti L, Nicoletti R, et al. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer. 2010;116:2208–14. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol. 2010;45:896–902. Araida T, Higuchi R, Hamano M, Kodera Y, Takeshita N, Ota T, et al. Should the extrahepatic bile duct be resected or preserved in R0 radical surgery for advanced gallbladder carcinoma? Results of a Japanese Society of Biliary Surgery Survey: a multicenter study. Surg Today. 2009;39:770–9. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia–dysplasia carcinoma sequence. Am J Surg Pathol. 2007;31:907–13. Pinedo HM, Peters GFJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988;6:1653–64. Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol. 1995;13:1663–70. Jiang W, Lu Z, He Y, Diasio RB. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res. 1997;3:395–9. McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumor. Br J Cancer. 1998;77:461–5. Yu Z, Sun J, Zhen J, Zhang Q, Yang Q. Thymidylate synthase predicts for clinical outcome in invasive breast cancer. Histol Histopathol. 2005;20:871–8. Obara S, Yamamoto K, Hosogai N, Yoshimura Y. Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma. Oral Oncol. 2005;41:276–82. Toi M, Ikeda T, Akiyama F, Kurosumi M, Tsuda H, Sakamoto G, et al. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. Int J Oncol. 2007;31:899–906. Baba H, Teramoto K, Kawamura T, Mori A, Imamura M, Arii S. Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol. 2003;52:469–76. Lassmann S, Hennig M, Rosenberg R, Nährig J, Schreglmann J, Krause F, et al. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors—correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis. 2006;21:238–47. Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K, et al. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. J Clin Oncol. 2000;18:3946–51. Nishi M, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, et al. Role of dihydropyrimidine dehydrogenase and thymidylate synthase expressions on immunohistochemistry in intrahepatic cholangiocarcinoma. Hepatol Res. 2011;41:64–70. Nii A, Shimada M, Ikegami T, Harino Y, Imura S, Morine Y, et al. Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma. Hepatol Res. 2009;39:274–81. Lord RV, Salonga D, Danenberg KD, Peters JH, De Meester TR, Park JM, et al. Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000;4:135–42. Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD, Fukushima M. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med. 2008;22:709–16. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol. 1996;14:1048–54. Artinyan A, Essani R, Lake J, Kaiser AM, Vukasin P, Danenberg P, et al. Molecular predictors of lymph node metastasis in colon cancer: increased risk with decreased thymidylate synthase expression. J Gastrointest Surg. 2005;9:1216–21. Lu ZH, Zhang R, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem. 1992;267:17102–9. Yokota H, Fernandez-Salguero P, Furuya H, Lin K, McBride OW, Podschun B, et al. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem. 1994;269:23192–6. Ishikawa M, Miyauchi T, Kashiwagi Y. Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy. BMC Cancer. 2008;8:188. Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol. 2003;8:72–8. Shimoda M, Sawada T, Kubota K. Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. Pathobiology. 2009;76:193–8.